• 2026-10-27 06:45:32

Australia's type 1 diabetes market presents opportunities for medical device companies, particularly in continuous glucose monitoring (CGM), as government subsidies support access to diabetes technologies. This article examines market growth, reimbursement arrangements and key Therapeutic Goods Administration (TGA) requirements, including Australian Register of Therapeutic Goods (ARTG) inclusion and unique device identification (UDI) compliance. It also explores opportunities across diabetes device categories and outlines practical considerations for companies planning to enter the Australian market.

• 2026-10-26 09:03:49

The Therapeutic Goods Administration (TGA) has published detailed regulatory guidance to help journalists, media organizations, and sponsors distinguish genuine public-interest news reporting from therapeutic goods advertising. Under the Therapeutic Goods Act 1989, media content that promotes the supply or use of regulated products—either directly or indirectly—is subject to strict advertising rules, including prohibitions on public promotion of prescription-only medicines. This article explores the legal distinction between independent journalism and promotional content, key indicators of unlawful advertising in news formats, statutory exceptions for broadcasters and publishers, and practical case studies provided by the regulatory authority.

• 2026-09-21 02:28:25

Australia's Therapeutic Goods Administration (TGA) updated its application audit selection criteria guidance, placing heightened pre-market focus on gynaecological curettes under Criterion 3 (Post-market signals). This article outlines how active post-market signals directly trigger non-mandatory application audits for medical devices, details the mandatory audit conditions under Regulation 5.3, and provides practical submission strategies for sponsors seeking Australian Register of Therapeutic Goods (ARTG) inclusion.

• 2026-08-25 03:20:19

Australian Institute of Health and Welfare (AIHW) recorded 323,497 elective lens-intervention admissions in 2024-25, with private hospitals accounting for 71.9% of recorded activity. With 98% of cataract surgeries delivered as same-day procedures and US$121.9M of ophthalmic instrument imports in 2025, the market combines substantial procedure activity with an established international supply channel. For global manufacturers, successful entry requires product-specific ARTG, sponsorship and UDI planning.

• 2026-07-27 04:05:50

Qualtech's recent webinar provided practical insights into medical device market entry in Australia and New Zealand, covering Australia's ARTG inclusion process, post-market obligations, new UDI requirements, and New Zealand's WAND notification framework. The session also highlighted key regulatory updates and practical considerations for manufacturers planning expansion into the ANZ market.

• 2026-07-28 02:39:21

Starting July 2026, the Australian Therapeutic Goods Administration (TGA) will implement an overall increase in regulatory fees and annual charges for medical devices and in vitro diagnostic (IVD) devices. This article provides a detailed 2025 versus 2026 fee comparison, highlighting an upward adjustment of approximately 4.7% to 6.3% across various submission and maintenance categories. It also includes strategic insights from Qualtech on leveraging overseas approvals and managing hidden compliance costs to optimize long-term operational budgets and market access strategies

• 2026-06-26 04:47:11

Australia's Unique Device Identification (UDI) system is moving from concept to reality, with the first mandatory compliance deadlines commencing in July 2026. Designed to strengthen patient safety, device traceability, and post-market surveillance, the phased implementation will introduce new obligations for both manufacturers and sponsors. This article explores how UDI works, key TGA compliance milestones, and what medical device companies should do to prepare.

• 2026-05-29 07:54:15

Join Qualtech's free webinar on June 18, 2026, to explore the latest regulatory developments and market access considerations for Australia and New Zealand. This session will provide practical insights into Australia TGA application pathways, key TGA updates in 2026, and the current regulatory framework in New Zealand, helping medical device manufacturers better prepare their ANZ market entry strategies.

• 2026-04-01 01:58:24

Musculoskeletal (MSK) conditions are a major health burden in Australia, ranking among the top 5 contributors to overall disease burden in 2024 and affecting nearly 7.3M people. Rising prevalence, aging demographics, and significant healthcare spending are driving growing demand for orthopedic technologies. As advanced solutions such as surgical robotics, smart implants, and regenerative therapies gain adoption, Australia's orthopedic sector continues to expand with increasing demand for innovative medical technologies.

• 2025-11-26 08:01:00

Artificial Intelligence (AI) is rapidly transforming healthcare in Australia, offering innovative solutions to meet the growing demands of an aging population and chronic disease management. With the AI healthcare market projected to reach AUD 1.78 billion by 2030, AI's potential to enhance early diagnosis and optimize treatments is substantial. Despite challenges like data fragmentation and regulatory complexities, AI is set to revolutionize healthcare delivery across the country.